Immune Design Competitors and Similar CompaniesClear all
Immune Design's competitors and similar companies include Enara Bio, ImmunoGen, Odyssey Therapeutics and Scorpion Therapeutics.
 Immune Design Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. |  Enara Bio Enara Bio (formerly known as Ervaxx) is a biotech company specializing in the use of Dark Antigens to deliver vaccines and other immunotherapies for treating and preventing cancer. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. |  Odyssey Therapeutics Odyssey Therapeutics is a company that develops precision immunomodulators and oncology medicines. | ||
Founding Date | Founding Date 2008 | Founding Date 2016 | Founding Date 1981 | Founding Date 2021 | Founding Date 2020 |
Type | Type Subsidiary | Type Private | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Seattle, US HQ South San Francisco, US | Locations Oxford, GB HQ London, GB London, GB Oxford, GB | Locations Waltham, US HQ | Locations Boston, US HQ Frankfurt Am Main, DE Ann Arbor, US San Diego, US | Locations Boston, US HQ Boston, US South San Francisco, US |
Employees | Employees 4813% decrease | Employees 622% increase | Employees 277161% increase | Employees 1481% decrease | Employees 1213% decrease |
Financial | |||||
Revenue (est.) | Revenue (est.) $2.2m (FY, 2018) | Revenue (est.) N/A | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $1.4m (FY, 2018) | Cost of goods N/A | Cost of goods $176k (FY, 2022) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $761k (FY, 2018) | Gross profit N/A | Gross profit $108.6m (FY, 2022) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($54.8m) (FY, 2018) | Net income N/A | Net income ($222.9m) (FY, 2022) | Net income N/A | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 17.5m (over 6 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 108m (over 5 years ago) |
Total funding raised | Total funding raised N/A | Total funding raised $ 17.5m | Total funding raised $ 56m | Total funding raised $ 386m | Total funding raised $ 108m |
For sources of this data, please see the company profile
View Company Profiles
Enara Bio
HQ
Oxford, GB
Employees
62↑ 2% increase
Enara Bio (formerly known as Ervaxx) is a biotech company specializing in the use of Dark Antigens to deliver vaccines and other immunotherapies for treating and preventing cancer.
View companyImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View companyOdyssey Therapeutics
HQ
Boston, US
Employees
148↓ 1% decrease
Odyssey Therapeutics is a company that develops precision immunomodulators and oncology medicines.
View company
Scorpion Therapeutics
HQ
Boston, US
Employees
121↓ 3% decrease
Scorpion Therapeutics is a company that develops cancer treatments.
View company